Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0XSNVX
ADC Name
36924655 ADC 14
Synonyms
ADC 14
   Click to Show/Hide
Organization
Seoul National University.
Drug Status
Investigative
Drug-to-Antibody Ratio
4
Structure
Antibody Name
Trastuzumab
  Antibody Info 
Antigen Name
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Site-specific conjugation via re-bridging.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (lC50) 
16.9
nM
CVCL_0419
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
18.8
nM
CVCL_0062
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
40.8
nM
CVCL_0125
Mammary carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 16.9 nM Moderate CD276 expression (CD276 ++)
Method Description
The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-468 cell.
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 18.8 nM Moderate CD276 expression (CD276 ++)
Method Description
The in vitro antitumor efficacy of ADC was assessed using the MDA-MB-231 cell.
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 40.8 nM High CD276expression (CD276 +++)
Method Description
The in vitro antitumor efficacy of ADC was assessed using the 4T1 cell.
In Vitro Model Mammary carcinoma 4T1 cells CVCL_0125
References
Ref 1 A Dual-Payload Antibody-Drug Conjugate Targeting CD276/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer